Amin Kavit R, Fildes James E
Blond McIndoe Laboratories, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Department of Plastic Surgery & Burns, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Front Surg. 2022 May 6;9:873507. doi: 10.3389/fsurg.2022.873507. eCollection 2022.
Twenty years have surpassed since the first vascularised composite allotransplantation (VCA) of the upper limb. This is an opportunity to reflect on the position of VCA as the gold standard in limb reconstruction. The paucity of recipients, tentative clinical outcomes, and insufficient scientific progress question whether VCA will remain a viable treatment option for the growing numbers of amputees. Bionic technology is advancing at a rapid pace. The prospect of widely available, affordable, safely applied prostheses with long-standing functional benefit is appealing. Progress in the field stems from the contributions made by engineering, electronic, computing and material science research groups. This review will address the ongoing reservations surrounding VCA whilst acknowledging the future impact of bionic technology as a realistic alternative for limb reconstruction.
自首例上肢血管化复合组织异体移植(VCA)手术过去已有二十年。借此机会,我们可以思考VCA作为肢体重建金标准的地位。接受手术的患者数量稀少、临床结果尚不稳定以及科学进展不足,这些都让人质疑VCA是否仍将是越来越多截肢患者可行的治疗选择。仿生技术正在飞速发展。广泛可得、价格亲民且安全应用的假肢有望带来长期功能益处,这一前景颇具吸引力。该领域的进展源于工程、电子、计算机和材料科学研究团队所做出的贡献。本综述将阐述围绕VCA持续存在的疑虑,同时认可仿生技术作为肢体重建现实替代方案的未来影响。